Duration of functional improvement from stem-cell infusion in ED typically extends 6–18 months, with some men reporting sustained benefit at 24 months. Durability correlates with baseline erectile reserve and ongoing cardiovascular risk-factor control. Some men experience gradual functional decline after 12–18 months, potentially requiring booster infusions or return to pharmacotherapy. Long-term assessment beyond 2 years is sparse in published literature. Psychological factors influence durability; men with improved confidence may maintain benefit longer. Complete freedom from phosphodiesterase-5 inhibitors beyond 2 years is uncommon; most responders achieve dose reduction or improved responsiveness rather than independence.
Erectile dysfunction (ED) arises from vascular insufficiency, endothelial dysfunction, smooth-muscle pathology, or neurogenic impairment — often clustering with metabolic syndrome, atherosclerosis, and diabetes. Stem-cell investigations focus on whether placental mesenchymal stem cells and exosome preparations can regenerate penile vasculature, restore endothelial nitric-oxide-dependent relaxation, and repair cavernous smooth-muscle tissue. With 35 registered trials and 5 currently recruiting, the biological rationale targets restoration of penile erectile mechanics through vascular and tissue regeneration. Early clinical data suggest potential for improving erectile function, increasing rigidity and tumescence duration, and potentially reducing pharmacological dependence on phosphodiesterase-5 inhibitors when stem-cell therapy complements standard medical management.
Am I a candidate? → · Erectile Dysfunction: full overview → · Erectile Dysfunction cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment